Brandon Folkes, an analyst from H.C. Wainwright, has initiated a new Buy rating on Xeris Pharmaceuticals (XERS).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brandon Folkes’s rating is based on the belief that Xeris Pharmaceuticals’ commercial assets, particularly Recorlev, have significant growth potential that is not fully appreciated by the market. Despite the strong performance of XERS stock in 2025, Folkes sees further appreciation potential due to the company’s ambitious revenue goals and the potential for Recorlev to exceed current consensus estimates if the company continues its successful execution.
Additionally, the potential of XP-8121, which is in development for hypothyroidism, adds to the long-term growth prospects of Xeris. The product could address a significant unmet need and generate substantial revenue, with the company projecting peak sales between $1 billion and $3 billion. This, combined with the company’s current trading metrics and the potential for continued outperformance of revenue expectations, supports Folkes’s Buy rating for Xeris Pharmaceuticals.
According to TipRanks, Folkes is an analyst with an average return of -6.4% and a 33.46% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Trevi Therapeutics, and ANI Pharmaceuticals.
In another report released on August 8, Oppenheimer also reiterated a Buy rating on the stock with a $8.00 price target.